Mirae Asset Global Investments Portfolio holdings
AUM
$28.7B
1-Year Return
20.96%
This Quarter Return
+4.4%
1 Year Return
+20.96%
3 Year Return
+114.88%
5 Year Return
+202.83%
10 Year Return
+496.23%
AUM
$24.6B
AUM Growth
+$2.03B
(+9%)
Cap. Flow
+$1.25B
Cap. Flow
% of AUM
5.09%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
1,702
New
151
Increased
731
Reduced
674
Closed
110
Top Buys
| 1 |
Vanguard S&P 500 ETF
VOO
|
$168M |
| 2 |
Apple
AAPL
|
$71.3M |
| 3 |
Microsoft
MSFT
|
$57.4M |
| 4 |
HDFC Bank
HDB
|
$44.6M |
| 5 |
Schwab US Dividend Equity ETF
SCHD
|
$40.5M |
Top Sells
| 1 |
Invesco QQQ Trust
QQQ
|
$83.3M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$81.2M |
| 3 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
$43.3M |
| 4 |
Broadcom
AVGO
|
$42.7M |
| 5 |
Advanced Micro Devices
AMD
|
$37.7M |
Sector Composition
| 1 | Technology | 33.15% |
| 2 | Consumer Discretionary | 10.25% |
| 3 | Communication Services | 8.94% |
| 4 | Healthcare | 6.61% |
| 5 | Financials | 5.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Stoke Therapeutics
STOK
$1.13B
| $19.5K | ﹤0.01% |
+1,765
| New | +$19.5K |
|
1427
Oric Pharmaceuticals
ORIC
$1.06B
| $19.4K | ﹤0.01% |
2,352
-199
| -8% | -$1.64K |
|
1428
Futu Holdings
FUTU
$26.1B
| $19.2K | ﹤0.01% |
238
| – | – |
|
|
GOOD
1429
Gladstone Commercial Corp
GOOD
$616M
| $19K | ﹤0.01% |
1,187
-368
| -24% | -$5.89K |
|
|
MESO
1430
Mesoblast
MESO
$1.84B
| $18.7K | ﹤0.01% |
+1,065
| New | +$18.7K |
|
1431
Phathom Pharmaceuticals
PHAT
$875M
| $18.6K | ﹤0.01% |
2,279
-191
| -8% | -$1.56K |
|
1432
Annexon
ANNX
$238M
| $18.4K | ﹤0.01% |
+3,552
| New | +$18.4K |
|
1433
Altimmune
ALT
$334M
| $18.2K | ﹤0.01% |
+2,370
| New | +$18.2K |
|
|
CAN
1434
Canaan Creative
CAN
$346M
| $18.2K | ﹤0.01% |
+8,182
| New | +$18.2K |
|
1435
Savara
SVRA
$643M
| $18K | ﹤0.01% |
5,719
-234
| -4% | -$737 |
|
|
LX
1436
LexinFintech Holdings
LX
$1.02B
| $17.7K | ﹤0.01% |
+2,999
| New | +$17.7K |
|
1437
Tourmaline Bio
TRML
$687M
| $17.7K | ﹤0.01% |
854
-73
| -8% | -$1.51K |
|
1438
Cartesian Therapeutics
RNAC
$277M
| $17.4K | ﹤0.01% |
4,562
+847
| +23% | +$3.24K |
|
1439
Astria Therapeutics
ATXS
$424M
| $17.2K | ﹤0.01% |
+1,881
| New | +$17.2K |
|
1440
Zeekr
ZK
$7.43B
| $17.1K | ﹤0.01% |
607
-22
| -3% | -$622 |
|
1441
Xeris Biopharma Holdings
XERS
$1.27B
| $17K | ﹤0.01% |
4,968
-421
| -8% | -$1.44K |
|
|
VERV
1442
DELISTED
Verve Therapeutics
VERV
| $17K | ﹤0.01% |
2,821
-240
| -8% | -$1.45K |
|
1443
Pacific Biosciences
PACB
$381M
| $17K | ﹤0.01% |
9,126
-731
| -7% | -$1.36K |
|
1444
ManpowerGroup
MAN
$1.91B
| $16.9K | ﹤0.01% |
+295
| New | +$16.9K |
|
1445
MindMed
MNMD
$702M
| $16.7K | ﹤0.01% |
+2,444
| New | +$16.7K |
|
|
WSR
1446
Whitestone REIT
WSR
$672M
| $16.6K | ﹤0.01% |
1,188
-460
| -28% | -$6.45K |
|
1447
CorMedix
CRMD
$926M
| $16.6K | ﹤0.01% |
+2,022
| New | +$16.6K |
|
1448
SPDR Blackstone Senior Loan ETF
SRLN
$6.97B
| $16.4K | ﹤0.01% |
394
-30
| -7% | -$1.25K |
|
1449
EyePoint Pharmaceuticals
EYPT
$966M
| $16.4K | ﹤0.01% |
2,274
+338
| +17% | +$2.43K |
|
1450
Terns Pharmaceuticals
TERN
$632M
| $16.3K | ﹤0.01% |
2,830
+285
| +11% | +$1.64K |
|